USA flag logo/image

An Official Website of the United States Government

High Throughput Metagenomic Drug Screening in Mammalian Cells

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96243
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
GM095227
Solicitation Year:
N/A
Solicitation Topic Code:
NIGMS
Solicitation Number:
N/A
Small Business Information
METAGENOMIX, INC.
41 CUMPSTONE RD HAMDEN, CT 06518-2424
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: High Throughput Metagenomic Drug Screening in Mammalian Cells
Agency: HHS
Contract: 1R43GM095227-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): In recent years there has been an increased interest in tapping the potential drug reservoir contained within the metagenome. To enable mammalian based screening of metagenomic libraries for novel drugs we have develope d a method for bacterial delivery of natural products. We demonstrate with the anticancer drug violacein that bacterial delivery of natural products is simple and removes the need for trial and error based extract preparation. Preliminary work with microfl uidic chips demonstrates the feasibility for high speed microdroplet formation using standard bacterial growth media. In Phase I we propose to extend this work by combining our bacterial drug delivery method with the power of microfluidic separation techno logy to carry out efficient, large-scale screening of the metagenome for novel natural products. It is expected that our technology will fulfill the unmet need for rapid discovery of new drugs to combat complex diseases such as cancer. PUBLIC HEALTH RELEVANCE: Approximately 22% of all deaths in the US are due to cancer, and it is estimated that by 2010 cancer will be responsible for more deaths worldwide than any other disease. Our novel method for screening the metagenome for bioactive molecules wil l allow us to add to the arsenal of natural products with potent anticancer activity. By utilizing bacteria as a source of drug production we will be assured of an almost limitless source of anticancer compound, avoiding a major bottleneck that would other wise limit product availability to patients.

Principal Investigator:

Elias Theodorou

Business Contact:

Elias Theodorou
Small Business Information at Submission:

METAGENOMIX, INC.
METAGENOMIX, INC. 41 CUMPSTONE RD HAMDEN, CT 06518

EIN/Tax ID: 127055615
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No